The therapeutic vaccines are a priority research line of the HIVACAT, the catalan programme for the development of therapeutic vaccines and prevention against the Human Immunodeficiency Virus (HIV). This type of therapeutic vaccine helps the patients who are carriers of the virus, combat infection and control the appearance of AIDS in the same way as with the current antiretroviral treatments. The final aim of the therapeutic vaccines will be to avoid a life long treatment with antiretroviral drugs. The research team ‘Infectious Diseases and AIDS’ led by Dr. Josep Maria Gatell from IDIBAPS – Hospital Clínic has developed using the brand HIVACAT, a model of the therapuetic vaccine based on the patient’s own dendritic cells. This reduction in the viral load is still considered to be insuficient but it is the first therapeutic vaccine which has achieved a postive response in the majority of patients.
The Journal PLoS Medicine has published a monograph of 12 articles which outline the main conclusions of the Malaria Eradication Research Agenda (malERA) initiative. This consultative process over a 2 year period has involved more than 250 scientists from all over the world with the aim of establishing a research and development agenda for the global eradication of malaria. The agenda does not prescribe specific activities, but proposes a communal vision between institutions and financial bodies with respect to the future of research and development related to malaria, with its eradication being the final aim.
This morning, the meeting to constitute the new José Carreras Research Institute against Leukaemia took place. The main aims of the new Institute are to promote the biomedical research of hematological malignancies, especially leukaemia, and also to develop preventative and personalized medicines in the same field. The meeting was attended by Mr. José Carreras in his role as president of the private International Foundation that took his name. In addition, he was joined by ministers, Marina Geli and Josep Huguet, the rector of the UAB, Ana Ripoll, the rector of the UB, Dídac Ramírez and the mayor of Badalona Jordi Sierra.
HEPTROMIC is the first research network funded by the European Commission devoted to the study of Hepatocellular Carcinoma (HCC). It is a 3-year translational research project which aims to solve core problems in the management of HCC, the third most common cause of cancer-related death worldwide. The partners taking part in this initiative have met today in Barcelona in the called kick-off meeting, which officially starts the project. Dr. Josep Maria Llovet, ICREA Research professor at IDIBAPS – Hospital Clínic, and his team lead that project which is meant to change the treatment of this cancer in the next years.
It is estimated that rare diseases -those whose frequency is under 5 cases / 10,000 people- affect about 6% of the European population. In the field of anemia, 1% of couples are at risk of having a newborn with a severe syndrome of hemoglobin. More than 330,000 children are born worldwide each year affected by one of these diseases, being the most common disorders sickle cell anemia and thalassemia syndromes. In Spain, the average risk of having a newborn with a rare or unusual anemia is being increased due to African immigration. However, Spain is working on that issue and is the fifth of the 27 member countries that has developed a Strategic plan for rare diseases. It has been emphasized by European Commission sources during the 3rd European Symposium organized by ENERCA at the Cosmocaixa Madrid.
The complexity of the immune system and nervous system turn Neuroimmunology into one of the most exciting fields of modern biomedicine. Between October 26th and 30th takes place in Sitges (Barcelona, Spain) the X International Congress of Neuroimmunology of the International Society of Neuroimmunology, coordinated by Dr. Pablo Villoslada, neurologist and head of the Neuroimmunology Center of the IDIBAPS – Hospital Clínic of Barcelona. This event highlights the advances that have been made in recent years thanks to new technologies, but also highlights the long road ahead. New biomarkers, potential immunotherapies, stem cell strategies and new discoveries about the natural history of neuroimmunological diseases are some of the issues that focus the attention of the 1,000 scientists attending the Congress.